a path forward ...

Prudent Biotech, Prudent Small Cap, Prudent Healthcare.

Each of these services are based on the quantitative investing approach.
The newsletter is a monthly publication with occasional intramonth updates, as needed.
You may learn more by clicking on the buttons below, which will open a new website.

Prudent Biotech

Biotechnology is a high-risk, high-reward industry driven by new drug discoveries and advancements in medical science. It is the largest industry group within the healthcare sector by the number of companies and significantly contributes to its performance. Our model portfolio includes up to 8 stocks and aims to outperform the Nasdaq Biotechnology Index. The Prudent Biotech Newsletter has been available to subscribers since January 2016.

Prudent Small Cap

Small Cap stocks represent a speculative market segment, targeting companies with market capitalizations between $200 million and $4 billion. Using a quantitatively-driven systematic investing approach, our model portfolio focuses on promising small cap and early-stage mid cap stocks. This segment offers significant capital appreciation opportunities but comes with higher volatility. The portfolio includes up to 10 stocks and aims to outperform the Russell 2000 Small Cap Index. This newsletter has been available since May 2003.

Prudent Healthcare

Healthcare is unique for its defensive characteristics and its dynamism, with some industry groups like pharmaceuticals and hospital services resisting economic downturns, while others like medical products, biotechnology, and medical services, driving medical evolution and innovation. Our model portfolio includes up to 10 stocks and seeks risk-adjusted returns that outperform the S&P Select Healthcare Index. This service launched in 2019 and became available for public subscription on Seeking Alpha in January 2020.

Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Prudent Small Cap, Prudent Biotech, and Prudent Healthcare newsletters. We are not a Registered Investment Advisor (RIA). Historical performance figures provided are hypothetical, unaudited, and based on our proprietary analysis and system performance, back-tested over an extended period. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve the financial risk of actual trading. The performance results obtained are intended for illustrative purposes only. No representation is being made that any account will or is likely to achieve profit or losses similar to those shown. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, the biotech industry and small caps are characterized by much higher risk and volatility than the general stock market. Information contained herein is general and does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your investment decisions. Use of the information herein is at one's own risk. We are simply sharing the results of our model. Nothing should be construed as a recommendation or an offer to buy or sell any securities, and we are not liable nor do we assume any liability or responsibility for losses incurred as a result of any information provided or not provided or not made available on time, herein or on our website or using any other medium. We cannot guarantee the accuracy and completeness of any information furnished by us. We may or may not have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or can be licensed and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their due diligence with any potential investment and consider obtaining professional advice before making an investment decision.

© Graycell Advisors. All rights reserved. Any act of copying, reproducing, or distributing this newsletter whether wholly or in part, for any purpose without the written permission of Graycell Advisors is strictly prohibited and shall be deemed to be copyright infringement.

© 2003-2024 Graycell Advisors. All Rights Reserved. USA

Page Created with OptimizePress